secwatch.observer — SEC 8-K summary
======================================

Issuer:     Petros Pharmaceuticals, Inc. (PTPI)
CIK:        0001815903
Form:       8-K
Filed at:   2021-11-16T23:59:59+00:00
Accession:  0001104659-21-139500
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Petros Pharma Q3 net sales fall 37% to $2.2M; net loss narrows to $1.7M
-----------------------------------------------------------------------

- Net sales $2.2M, down from $3.5M YoY; Prescription Medicines net sales declined 47% due to higher allowances and returns.
- Net loss improved to $1.7M vs $3.3M YoY; adjusted EBITDA loss $1.9M.
- Record STENDRA prescriptions and tablet sales; total mg sold up 6% sequentially.
- Completed enrollment of pivotal label comprehension study for OTC switch of STENDRA; no FDA-approved OTC ED drug exists.
- Cash $8.1M at Sep 30; raised $5.3M net in October 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815903/000110465921139500/0001104659-21-139500-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815903/000110465921139500/tm2133040d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-139500

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer